Canada-based Psyence Biomed has completed a merger with Newcourt Acquisition Corp. (NASDAQ: NCAC), making the palliative care-focused psychedelics company publicly traded in the United States. Psyence Biomed is a subsidiary of the Canadian biotech company Psyence Group Inc. Psyence is publicly traded on the Canadian Securities Exchange and has made natural psychedelic products the focus […]
A new, publicly traded company devoted to exploring the use of psychedelics in palliative care is in development. Psyence Biomed, a subsidiary of the Canadian biotech company Psyence Group Inc., has signed a definitive business combination agreement with Newcourt Acquisition Corp. (NASDAQ: NCAC) to create the new organization. Psyence Biomed expects to receive a minimum […]
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
